ClinicalTrials.gg
RecruitingNCT05019495Updated Jan 6, 2026

Optimizing Tobacco Treatment Delivery for People Living With HIV

An interventional study of PrOMOTE in Hiv and Smoking, Cigarette, sponsored by Medical University of South Carolina. Recruiting at 1 site in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-01-06.

Primary conditionCigarette SmokingRegistry: Acquired Immunodeficiency SyndromeReclassifiedWhy we changed it
Registry
Acquired Immunodeficiency Syndrome — the first condition term the registry derived for this study.
ClinicalTrials.gg
Cigarette Smoking
Why
  1. The registry often attaches Acquired Immunodeficiency Syndrome to studies about something else, and this study's title and listed conditions do not name it.
  2. The study's listed conditions name Cigarette Smoking.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Medical University of South Carolina · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2021; still recruiting 4 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
231
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Cigarette Smoking by Medical University of South Carolina — 6 open to participants now, 6 under way, none of them phase 3. Cigarette Smoking · Medical University of South Carolina.

Planned enrollment
4th of 15
231 · median 99
Started
2021
with 2 others
No phase
9 of 15
5 open now
Registered
9th of 15
by date

Among the 15 studies in Cigarette Smoking by Medical University of South Carolina, this one is the 4th largest by planned enrollment, is one of 3 that started in 2021, is one of 9 with no phase, and was the 9th registered.

Cigarette Smoking

477 studies on the registry are indexed under Cigarette Smoking; 87 are open to participants now.

Browse Cigarette Smoking studies →

Open to participants now

6 of the 15 studies in Cigarette Smoking by Medical University of South Carolina are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 62 Cigarette Smoking studies recruiting now, 38 (61%) set no upper age limit and 18 (29%) stop at 75 or younger; 1 takes children under 18; 33 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Cigarette Smoking by Medical University of South Carolina, or all of them as a file.
02

Study summary

The purpose of this study is to conduct a randomized trial to evaluate a proactive, opt-out model of provider contact to deliver smoking cessation support for people living with HIV compared to standard care support delivered through traditional clinic pathways. Investigators will also evaluate implementation outcomes to identify barriers and facilitators towards future implementation. Investigators hope to define best practices and optimize the delivery of smoking cessation interventions for people living with HIV.

Read the detailed description

This hybrid effectiveness-implementation trial presents on opportunity to optimize tobacco treatment delivery for people living with HIV (PLWH), and identify barriers and facilitators towards future implementation. We are proposing a comparison of Treatment As Usual (TAU; reactive, opt-in tobacco treatment using standard clinical pathways) vs Proactive Outreach with Medication Opt-out for Tobacco Treatment Engagement (PrOMOTE). Participants will be randomized in a 1:1 allocation. The primary aim is to compare rates of cessation and quit attempts at the Week 12 follow-up between participants who received TAU versus PrOMOTE. As a secondary aim we will characterize key determinants of PrOMOTE reach, implementation fidelity, adherence, and acceptability. We hypothesize that the PrOMOTE intervention will increase cessation rates and number of quit attempts, and that it will result in greater reach and pharmacotherapy delivery compared to TAU. Key determinants of PrOMOTE implementation outcomes will also be characterized. An exploratory assessment of CD4 cell count and HIV viral load, in addition to durability of smoking cessation outcomes, will also be assessed. By optimizing the delivery of effective tobacco treatments for PLWH, we hope to increase the number of people receiving tobacco treatment, increase tobacco cessation rates, and reduce the risk of morbidity and mortality from smoking-related causes.

03

Conditions studied

  • Hiv
  • Smoking, Cigarette

Browse trials for

Keywords

  • Smoking
04

In context

Cigarette Smoking Reclassified

477 studies on the registry are indexed under Cigarette Smoking; 87 are open to participants now.

This study's planned enrollment of 231 is above the median of 96 across 407 interventional studies indexed under Cigarette Smoking.

Browse Cigarette Smoking studies →

Lead sponsor

Medical University of South Carolina is the lead sponsor of 875 studies on the registry; 165 are open to participants now.

Of its 132 completed or terminated interventional studies of FDA-regulated products, 104 (79%) have results posted.

Compared within Cigarette Smoking, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Acquired Immunodeficiency Syndrome. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 21 and older
  • Current diagnosis of
  • Current smoker (defined as self-report of current smoking)
  • Willing to be randomized
  • English speaking

Exclusion criteria

Exclusion Criteria:

  • Currently taking part in any other tobacco treatment program or using cessation medication (i.e., taking nicotine replacement therapy or other cessation medications, enrolled in the Quitline, or in another study)
  • Currently imprisoned
  • Pregnant women
  • Non-English speaking persons
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
231 participants (estimated)

Study arms

  • No intervention
    Treatment as Usual

    Treatment as Usual (TAU) participants will follow traditional clinic pathways for receiving tobacco treatment in the Medical University of South Carolina Health Infectious Disease outpatient clinic. All patients randomized to TAU will have the opportunity to access smoking cessation pharmacotherapy from the Infectious Disease clinical pharmacist.

  • Experimental
    ProMOTE

    In the PrOMOTE group, the participants will be contacted by the clinical pharmacist on the tobacco treatment staff three times for medication prescriptions and refills. They will also receive brief counseling and motivational interviewing by the clinical pharmacist.

    Behavioral: PrOMOTE

Interventions

  • BehavioralPrOMOTE

    This is an opt-out, proactive approach to tobacco treatment by a clinical pharmacy specialist. The pharmacist will call patients and offer an individualized pharmacotherapy prescription. The patient must opt-out for it not to be sent to their pharmacy. The patient will also receive brief motivational interviewing and behavioral counseling from the pharmacist.

    Also known as: Proactive Outreach with Medication Opt-out for Tobacco Treatment Engagement

07

What researchers measure

Primary outcomes

  1. Tobacco use abstinence

    Self-reported and confirmed by breath carbon monoxide test

    Time frame: 7 days

Secondary outcomes

  1. Reach

    Percentage of current smokers engaged in an intervention

    Time frame: 24 weeks (study completion)

  2. Fidelity of intervention

    The extent to which an intervention is implemented as intended. This will be collected via interviews with patients and providers.

    Time frame: 24 weeks (study completion)

  3. Fidelity of intervention

    The extent to which an intervention is implemented as intended. This will be collected via surveys.

    Time frame: 24 weeks (study completion)

  4. Perceived barriers to the outcomes

    Using the implementation tracking checklist, provider perceptions of barriers faced in completion of intervention steps will be monitored. These will be collected via interviews with patients.

    Time frame: 24 weeks (study completion)

  5. Perceived barriers to the outcomes

    Using the implementation tracking checklist, provider perceptions of barriers faced in completion of intervention steps will be monitored. These will be collected via interviews with providers.

    Time frame: 24 weeks (study completion)

  6. Acceptability of intervention

    The perception among stakeholders that the treatment is agreeable or satisfactory. This will be collected via interviews with patients and providers.

    Time frame: 24 weeks (study completion)

  7. Acceptability of intervention

    The perception among stakeholders that the treatment is agreeable or satisfactory. This will be collected via surveys.

    Time frame: 24 weeks (study completion)

08

Study locations

1 of 1 sites recruiting
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
    Recruiting
    • Chloe Morone · Contact843-637-0734
09

References and documents

Publications

  • Sanford BT, Toll BA, Eckard AR, Sterba KR, Cummings KM, Baker NL, Rojewski AM. Optimizing tobacco treatment delivery for people with HIV: trial protocol for a randomized controlled trial. Addict Sci Clin Pract. 2022 Nov 5;17(1):61. doi: 10.1186/s13722-022-00341-2. PubMed 36335376 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2021 (actual). Primary completion is estimated for Feb 2027, 62 months after the start.

Of 185 non-industry interventional studies with no phase under Cigarette Smoking, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 33. This study's planned 62 months is above that.

Counting every sponsor, half of 192 studies reached it within 20 months; a quarter within 8 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2021
First posted
Aug 24, 2021
StartActual
Dec 1, 2021
Primary completionEst.
Feb 1, 2027
CompletionEst.
Feb 28, 2027
Last update
Jan 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05019495
Responsible party
Alana Rojewski (Assistant Professor, Medical University of South Carolina) — Principal investigator
First posted
Aug 24, 2021
Start date
Dec 1, 2021
Primary completion
Feb 1, 2027 (estimated)
Completion
Feb 28, 2027 (estimated)
Last update
Jan 6, 2026

Study contacts

Chloe Morone
Contact
morone@musc.edu
843-637-0734
Alana Rojewski
Contact
rojewski@musc.edu
8438761593

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion